Health Technology Assessment of Novel Biologic Therapies: A Budget Impact Analysis for National Health Systems

Authors

  • Nagy L Department of Health Economics, Semmelweis University, Budapest, Hungary Author
  • Ekstrom S Department of Health Technology Assessment, Karolinska Institute, Stockholm, Sweden Author
  • Nielsen M Department of Pharmacoeconomics, University of Copenhagen, Copenhagen, Denmark Author

DOI:

https://doi.org/10.5281/zenodo.22650202

Keywords:

budget impact analysis, health technology assessment, biologic therapies, biosimilars, gene therapy reimbursement

Abstract

Background: Biologic therapies, including monoclonal antibodies and gene and cell therapies, have transformed treatment in
oncology, rheumatology, and immunology, but their cost places sustained pressure on national health system budgets, prompting
health technology assessment (HTA) bodies to pair cost-effectiveness evidence with budget impact analysis (BIA). Objective: This
case study synthesizes published literature on BIA methodology and its application to biologic therapies, describing how HTA
agencies and payers have evaluated biosimilar entry, high-cost specialty biologics, and gene and cell therapies, and comparing
reported budget impact findings across national health systems. Methods: We conducted a narrative, applied synthesis of
methodological guidance from ISPOR, CADTH, and NICE, together with published disease-area BIA case studies in oncology,
rheumatology, and rare-disease gene therapy, and cross-country comparative analyses of biologic and biosimilar pricing and
reimbursement policy; findings are reported as a synthesis of previously published figures, with no new primary budget model
estimated. Findings: Methodological guidance converges on core principles-payer-relevant time horizon, explicit uptake and
comparator assumptions, and mandatory sensitivity analysis-yet implementation varies across jurisdictions. Biosimilar entry is
consistently associated with reduced biologic spending in oncology (rituximab, trastuzumab, denosumab) and
immunology/rheumatology (adalimumab, filgrastim), with reported savings ranging from single digits to over 20% depending on
uptake speed and procurement policy. Gene therapy budget impact models for conditions such as sickle cell disease show high
per-patient one-time costs that remain a small share of aggregate pharmacy spending, though pipeline-level projections suggest
cumulative impact will grow. Cross-country comparisons show that biosimilar uptake and procurement policy, not clinical
evidence, are the principal drivers of divergent realized savings between health systems. Conclusions: BIA is an established,
methodologically codified complement to cost-effectiveness analysis for biologics, but reported budget impact magnitude is highly
sensitive to policy choices under payers' direct control. Strengthening cross-jurisdictional comparability of BIA reporting and
extending good practice to gene and cell therapies are priorities for HTA methodology.

References

Simoens S, Jacobs I, Popovian R, Isakov L, Shane LG (2017) Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis. PharmacoEconomics, 35(10):1047-1062, DOI:10.1007/s40273-017-0529-x.

Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P (2007) Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices-Budget Impact Analysis. Value in Health, 10(5):336-347, DOI:10.1111/j.1524-4733.2007.00187.x.

Sullivan SD, Mauskopf JA, Augustovski F, Caro JJ, Lee KM, Minchin M, Orlewska E, Penna P, Rodriguez Barrios JM, Shau WY (2014) Budget Impact Analysis-Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value in Health, 17(1):5-14, DOI:10.1016/j.jval.2013.08.2291.

Grewal S, Ramsey S, Balu S, Carlson JJ (2018) Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim. Expert Review of Pharmacoeconomics & Outcomes Research, 18(4):447-454, DOI:10.1080/14737167.2018.1476142.

Marshall DA, Douglas PR, Drummond MF, Torrance GW, MacLeod S, Manti O, Cheruvu L, Corvari R (2008) Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada. PharmacoEconomics, 26(6):477-495, DOI:10.2165/00019053-200826060-00003.

Foroutan N, Tarride JE, Xie F, Levine M (2018) A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions. ClinicoEconomics and Outcomes Research, 10:821-854, DOI:10.2147/ceor.s178825.

Angelis A, Harker M, Cairns J, Seo MK, Legood R, Miners A, Wiseman V, Chalkidou K, Grieve R, Briggs A (2023) The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual. Value in Health, 26(10):1503-1509, DOI:10.1016/j.jval.2023.05.015.

Dawoud D, Lamb A, Moore A, Bregman C, Rupniewska E, Paling T, Wolfram V, Lovett RES, Dent R (2022) Capturing what matters: updating NICE methods guidance on measuring and valuing health. Quality of Life Research, 31(7):2167-2173, DOI:10.1007/s11136-022-03101-6.

Cowles E, Marsden G, Cole A, Devlin N (2017) A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact? Applied Health Economics and Health Policy, 15(4):469-477, DOI:10.1007/s40258-017-0309-y.

Toumi M, Dabbous O, Aballea S, Drummond MF, Graf von der Schulenburg JM, Malone DC, Neumann PJ, Sullivan SD, Tunis S (2023) Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal. Expert Review of Pharmacoeconomics & Outcomes Research, 23(5):483-497, DOI:10.1080/14737167.2023.2197214.

Jang M, Simoens S, Kwon T (2021) Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets. BioDrugs, 35(1):89-101, DOI:10.1007/s40259-020-00461-8.

Giuliani J, Bonetti A (2019) The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab. Anticancer Research, 39(7):3971-3973, DOI:10.21873/anticanres.13552.

Huang HY, Liu CC, Yu Y, Wang L, Wu DW, Guo LW, Wang SH, Fang H, Bai Y, Fang Y, Fan Q, Sun C, Wu Y, Shi JF, Ma F, Tang Y, Dai M, Li N (2020) Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review. Frontiers in Pharmacology, 11:572569, DOI:10.3389/fphar.2020.572569.

Chaplin S, van Stiphout J, Chen A, Li E (2024) Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective. Journal of Managed Care & Specialty Pharmacy, 30(11):1226-1238, DOI:10.18553/jmcp.2024.24036.

Flanigan J, Chaplin S, van Stiphout J, Schauf M, Tindal M, Gundlach A, Li E, Lyman GH (2025) A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology population. Journal of Medical Economics, 28(1):2027-2038, DOI:10.1080/13696998.2025.2584885.

Ferrufino CP, Munakata J, Wei W, Proudfoot C, Kuznik A, Boklage SH, Chen CI (2018) Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies. ClinicoEconomics and Outcomes Research, 10:805-819, DOI:10.2147/ceor.s163829.

DeMartino P, Haag MB, Hersh AR, Caughey AB, Roth JA (2021) A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease. JAMA Pediatrics, 175(6):617-619, DOI:10.1001/jamapediatrics.2020.7140.

DeMartino PC, Haag MB, Caughey AB, Roth JA (2024) A budget impact analysis of gene therapy for sickle cell disease: an updated analysis. Blood Advances, 8(17):4658-4661, DOI:10.1182/bloodadvances.2024013093.

Wong CH, Li D, Wang N, Gruber J, Lo AW, Conti RM (2023) The estimated annual financial impact of gene therapy in the United States. Gene Therapy, 30(10-11):761-773, DOI:10.1038/s41434-023-00419-9.

Kawalec P, Stawowczyk E, Tesar T, Skoupa J, Turcu-Stiolica A, Dimitrova M, Petrova GI, Rugaja Z, Männik A, Harsanyi A, Draganic P (2017) Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries. Frontiers in Pharmacology, 8:288, DOI:10.3389/fphar.2017.00288.

Machado S, Cruz A, Ferreira PL, Morais C, Pimenta RE (2024) Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review. Frontiers in Public Health, 12:1263472, DOI:10.3389/fpubh.2024.1263472.

Vogler S, Schneider P, Zuba M, Busse R, Panteli D (2021) Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure. Frontiers in Pharmacology, 12:625296, DOI:10.3389/fphar.2021.625296.

Downloads

Published

2024-06-14